{"id":412758,"date":"2021-01-12T07:01:35","date_gmt":"2021-01-12T12:01:35","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=412758"},"modified":"2021-01-12T07:01:35","modified_gmt":"2021-01-12T12:01:35","slug":"cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/","title":{"rendered":"CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Preliminary Full Year and Q4 2020 Product Sales were $39.5 million and $11.5 million, respectively, representing growth of 73% and 74%, respectively, over the corresponding prior periods.  Cumulative CytoSorb treatments surpassed 121,000.<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">MONMOUTH JUNCTION, N.J.<\/span>, <span class=\"xn-chron\">Jan. 12, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0<u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=2003904139&amp;u=http%3A%2F%2Fwww.cytosorbents.com%2F&amp;a=CytoSorbents+Corporation\" rel=\"nofollow noopener noreferrer\">CytoSorbents Corporation<\/a><\/u>\u00a0(NASDAQ: CTSO), a critical care immunotherapy leader commercializing its <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=1622928390&amp;u=http%3A%2F%2Fwww.cytosorb.com%2F&amp;a=CytoSorb%C2%AE\" rel=\"nofollow noopener noreferrer\">CytoSorb\u00ae<\/a>\u00a0blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, pre-announces preliminary unaudited fourth quarter 2020 and full-year 2020 results ahead of filing its Form 10-K.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\" title=\"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb.  CytoSorb is approved in the European Union and distributed in 58 countries worldwide. (PRNewsfoto\/CytoSorbents Corporation)\" alt=\"CytoSorbents Corporation (NASDAQ: CTSO) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb.  CytoSorb is approved in the European Union and distributed in 58 countries worldwide. (PRNewsfoto\/CytoSorbents Corporation)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p \/>\n<div id=\"divReleaseHighlighte27c\">CytoSorbents (NASDAQ: CTSO) Pre-announces Record Preliminary Unaudited 2020 Quarterly and Annual Revenue with 73% Growth<\/div>\n<p>\n        <b>Preliminary 2020 Financial Highlights:<\/b>\n      <\/p>\n<p \/>\n<p>\n        <b>The Company expects to announce the following: <\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Cumulative CytoSorb treatments delivered exceeded 121,000, up from 80,000 at the end of 2019 <\/li>\n<li>Preliminary 2020 unaudited Total Revenue, which includes product sales and grant revenue, was approximately <span class=\"xn-money\">$40.8 million<\/span> versus <span class=\"xn-money\">$24.9 million<\/span> in 2019 <\/li>\n<li>Preliminary 2020 unaudited Product Sales increased 73% to approximately <span class=\"xn-money\">$39.5 million<\/span>, from <span class=\"xn-money\">$22.8 million<\/span> in 2019, driven by strength across all sales units <\/li>\n<li>Preliminary Q4 2020 unaudited Total Revenue was approximately <span class=\"xn-money\">$11.8 million<\/span> versus <span class=\"xn-money\">$7.4 million<\/span> in Q4 2019 <\/li>\n<li>Preliminary Q4 2020 unaudited Product Sales rose 74% to approximately <span class=\"xn-money\">$11.5 million<\/span>, compared to <span class=\"xn-money\">$6.6 million<\/span> in Q4 2019 <\/li>\n<li>Preliminary blended product gross margins are expected to approach 80% for Q4 2020, mixing higher margin direct and lower margin distributor and partner sales <\/li>\n<li>Strong cash balance at the end of 2020 was in excess of <span class=\"xn-money\">$71 million<\/span>, following the repayment of the <span class=\"xn-money\">$15 million<\/span> term loan from Bridge Bank in Q4 2020<\/li>\n<\/ul>\n<p>Dr. <span class=\"xn-person\">Phillip Chan<\/span>, Chief Executive Officer of CytoSorbents stated, &#8220;Our record financial performance in 2020 reflects the underlying strength of our core businesses in critical care and cardiac surgery, aided by broad-based demand for CytoSorb as a powerful therapy to treat cytokine storm and hyperinflammation in mechanically ventilated COVID-19 patients.\u00a0 By leveraging our existing businesses, with new opportunities such as liver disease and the removal of blood thinners in cardiothoracic surgery, we believe 2021 will be another year of strong growth.\u00a0 We plan to provide more detail on the year ahead in a stockholder&#8217;s letter later this month.&#8221;<\/p>\n<p>\n        <b>About CytoSorbents Corporation (<\/b><br \/>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=3398050673&amp;u=https%3A%2F%2Fwww.nasdaq.com%2Fmarket-activity%2Fstocks%2Fctso&amp;a=NASDAQ%3A%C2%A0CTSO\" rel=\"nofollow noopener noreferrer\">NASDAQ:\u00a0CTSO<\/a><br \/>\n        <b>)<\/b>\n      <\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=3138269725&amp;u=https%3A%2F%2Fcytosorbents.com%2F&amp;a=CytoSorbents+Corporation\" rel=\"nofollow noopener noreferrer\">CytoSorbents Corporation<\/a>\u00a0is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=1622928390&amp;u=http%3A%2F%2Fwww.cytosorb.com%2F&amp;a=CytoSorb%C2%AE\" rel=\"nofollow noopener noreferrer\">CytoSorb\u00ae<\/a>\u00a0is approved in the European Union with distribution in 67 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the &#8220;cytokine storm&#8221; or &#8220;cytokine release syndrome&#8221; that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=1622928390&amp;u=http%3A%2F%2Fwww.cytosorb.com%2F&amp;a=CytoSorb%C2%AE\" rel=\"nofollow noopener noreferrer\">CytoSorb\u00ae<\/a>\u00a0is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorb\u00ae has been used in more than 121,000 human treatments to date.\u00a0 CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma) and both <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=1005327578&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fcytosorb-is-approved-and-available-for-the-removal-of-ticagrelor-a-leading-anti-platelet-drug-during-cardiopulmonary-bypass-in-the-eu-300995215.html&amp;a=ticagrelor\" rel=\"nofollow noopener noreferrer\">ticagrelor<\/a>\u00a0and <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=158238465&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fcytosorb-is-eu-approved-to-remove-rivaroxaban-a-leading-factor-xa-inhibitor-and-novel-oral-anticoagulant-during-on-pump-cardiothoracic-surgery-301057276.html&amp;a=rivaroxaban\" rel=\"nofollow noopener noreferrer\">rivaroxaban<\/a>\u00a0during cardiothoracic surgery.\u00a0 CytoSorb has also received <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=1097991930&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fus-fda-grants-cytosorb-emergency-use-authorization-for-use-in-patients-with-covid-19-infection-301039293.html&amp;a=FDA+Emergency+Use+Authorization\" rel=\"nofollow noopener noreferrer\">FDA Emergency Use Authorization<\/a>\u00a0in <span class=\"xn-location\">the United States<\/span> for use in critically ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances.\u00a0 CytoSorb has also been granted <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=1786416048&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fdevelopment-update-us-fda-grants-breakthrough-designation-to-cytosorb-for-removal-of-ticagrelor-during-cardiopulmonary-bypass-in-emergent-and-urgent-cardiothoracic-surgery-301043326.html&amp;a=FDA+Breakthrough+Designation\" rel=\"nofollow noopener noreferrer\">FDA Breakthrough Designation<\/a>\u00a0for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.<\/p>\n<p>CytoSorbents&#8217; purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than <span class=\"xn-money\">$38 million<\/span> from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF\/AFMC), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including ECOS-300CY\u2122, CytoSorb-XL\u2122, HemoDefend-RBC\u2122, HemoDefend-BGA\u2122, VetResQ\u2122, K<sup>+<\/sup>ontrol\u2122, ContrastSorb, DrugSorb, and others.\u00a0 \u00a0\u00a0For more information, please visit the Company&#8217;s websites at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=4280956861&amp;u=https%3A%2F%2Fcytosorbents.com%2F&amp;a=www.cytosorbents.com\" rel=\"nofollow noopener noreferrer\">www.cytosorbents.com<\/a>\u00a0and <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=2407417490&amp;u=http%3A%2F%2Fwww.cytosorb.com%2F&amp;a=www.cytosorb.com\" rel=\"nofollow noopener noreferrer\">www.cytosorb.com<\/a>\u00a0or follow us on <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=1639383026&amp;u=https%3A%2F%2Fwww.facebook.com%2Fcytosorbents&amp;a=Facebook\" rel=\"nofollow noopener noreferrer\">Facebook<\/a>\u00a0and <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=2218827135&amp;u=https%3A%2F%2Ftwitter.com%2FCytoSorbents&amp;a=Twitter\" rel=\"nofollow noopener noreferrer\">Twitter<\/a>.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions, including, but not limited to, statements regarding our plans to leverage our existing business for future growth and to deliver a stockholders letter, and are not historical facts and typically are identified by use of terms such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management&#8217;s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, risks discussed in our Annual Report on Form 10-K, filed with the SEC on <span class=\"xn-chron\">March 5, 2020<\/span>, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements, particularly in light of the current coronavirus pandemic, where businesses can be impacted by rapidly changing state and federal regulations, as well as the health and availability of their workforce. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.<\/p>\n<p>\n        <b>Please Click to Follow Us on <\/b><br \/>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=1639383026&amp;u=https%3A%2F%2Fwww.facebook.com%2Fcytosorbents&amp;a=Facebook\" rel=\"nofollow noopener noreferrer\">Facebook<\/a><br \/>\n        <b>\u00a0and <\/b><br \/>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3034162-1&amp;h=2218827135&amp;u=https%3A%2F%2Ftwitter.com%2FCytoSorbents&amp;a=Twitter\" rel=\"nofollow noopener noreferrer\">Twitter<\/a>\n      <\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tr>\n<td class=\"prnsbt1 prnsbr1 prnvab prnsbb1 prnpl6 prnsbl1 prnpr6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Cytosorbents Contact:<\/b><\/p>\n<p class=\"prnews_p\" \/>\n<p class=\"prnews_p\">\n                    <span class=\"prnews_span\">Amy Vogel<br \/><\/span>\n                  <\/p>\n<p>                <\/span><br \/>\n                <span class=\"prnews_span\">Investor Relations<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">732-398-5394<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"mailto:avogel@cytosorbents.com\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">avogel@cytosorbents.com<\/a>\u00a0<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\" \/>\u00a0<\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Investor Relations Contact:<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Jeremy Feffer<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">LifeSci Advisors<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">917-749-1494<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"mailto:jeremy@lifesciadvisors.com\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">jeremy@lifesciadvisors.com<\/a><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\" \/>\u00a0<\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Public Relations Contact:<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Eric Kim<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Rubenstein Public Relations<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">212-805-3055<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"mailto:ekim@rubensteinpr.com\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">ekim@rubensteinpr.com<\/a><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\" \/>\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY45529&amp;sd=2021-01-12\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue-301206032.html\">http:\/\/www.prnewswire.com\/news-releases\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue-301206032.html<\/a><\/p>\n<p>SOURCE  CytoSorbents Corporation<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY45529&amp;Transmission_Id=202101120658PR_NEWS_USPR_____NY45529&amp;DateId=20210112\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Preliminary Full Year and Q4 2020 Product Sales were $39.5 million and $11.5 million, respectively, representing growth of 73% and 74%, respectively, over the corresponding prior periods. Cumulative CytoSorb treatments surpassed 121,000. PR Newswire MONMOUTH JUNCTION, N.J., Jan. 12, 2021 \/PRNewswire\/ &#8212;\u00a0CytoSorbents Corporation\u00a0(NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb\u00ae\u00a0blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, pre-announces preliminary unaudited fourth quarter 2020 and full-year 2020 results ahead of filing its Form 10-K. CytoSorbents (NASDAQ: CTSO) Pre-announces Record Preliminary Unaudited 2020 Quarterly and Annual Revenue with 73% Growth Preliminary 2020 Financial Highlights: The Company expects to announce the following: Cumulative CytoSorb treatments delivered exceeded 121,000, up from 80,000 at &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-412758","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Preliminary Full Year and Q4 2020 Product Sales were $39.5 million and $11.5 million, respectively, representing growth of 73% and 74%, respectively, over the corresponding prior periods. Cumulative CytoSorb treatments surpassed 121,000. PR Newswire MONMOUTH JUNCTION, N.J., Jan. 12, 2021 \/PRNewswire\/ &#8212;\u00a0CytoSorbents Corporation\u00a0(NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb\u00ae\u00a0blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, pre-announces preliminary unaudited fourth quarter 2020 and full-year 2020 results ahead of filing its Form 10-K. CytoSorbents (NASDAQ: CTSO) Pre-announces Record Preliminary Unaudited 2020 Quarterly and Annual Revenue with 73% Growth Preliminary 2020 Financial Highlights: The Company expects to announce the following: Cumulative CytoSorb treatments delivered exceeded 121,000, up from 80,000 at &hellip; Continue reading &quot;CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-12T12:01:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue\",\"datePublished\":\"2021-01-12T12:01:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\\\/\"},\"wordCount\":1024,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\\\/\",\"name\":\"CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"datePublished\":\"2021-01-12T12:01:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1096384\\\/CytoSorbents_Working_To_Save_Lives_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/","og_locale":"en_US","og_type":"article","og_title":"CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue - Market Newsdesk","og_description":"Preliminary Full Year and Q4 2020 Product Sales were $39.5 million and $11.5 million, respectively, representing growth of 73% and 74%, respectively, over the corresponding prior periods. Cumulative CytoSorb treatments surpassed 121,000. PR Newswire MONMOUTH JUNCTION, N.J., Jan. 12, 2021 \/PRNewswire\/ &#8212;\u00a0CytoSorbents Corporation\u00a0(NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb\u00ae\u00a0blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world, pre-announces preliminary unaudited fourth quarter 2020 and full-year 2020 results ahead of filing its Form 10-K. CytoSorbents (NASDAQ: CTSO) Pre-announces Record Preliminary Unaudited 2020 Quarterly and Annual Revenue with 73% Growth Preliminary 2020 Financial Highlights: The Company expects to announce the following: Cumulative CytoSorb treatments delivered exceeded 121,000, up from 80,000 at &hellip; Continue reading \"CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-12T12:01:35+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue","datePublished":"2021-01-12T12:01:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/"},"wordCount":1024,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/","name":"CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","datePublished":"2021-01-12T12:01:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1096384\/CytoSorbents_Working_To_Save_Lives_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytosorbents-reports-preliminary-fourth-quarter-and-full-year-2020-revenue\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412758","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=412758"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/412758\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=412758"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=412758"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=412758"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}